» » » Cough Syrup Deaths: CAG Flagged Tamil Nadu’s Drug Test Shortfall Year Before Fatal Incidents, Says Report

Cough Syrup Deaths: CAG Flagged Tamil Nadu’s Drug Test Shortfall Year Before Fatal Incidents, Says Report

,

 Here’s a summary of what I found about the CAG’s warning and how it relates to the recent cough syrup deaths, along with what the report says and what gaps were identified:

What the CAG Report Found

According to a report by the Comptroller & Auditor General of India (CAG), tabled in the Tamil Nadu Assembly on December 10, 2024, covering the period 2016-22, there were serious shortfalls in the state’s drug regulatory and quality control system. 

Some key points:

  • Inspections: The drug control authorities in Tamil Nadu did only ~61% of the planned/targeted drug inspections between 2016-17 and 2020-21.

  • Sample Collection: They collected only about ~49% of the required number of drug samples for laboratory testing in that period. 

  • Manpower Shortage: Of the sanctioned strength of 488 drug inspectors, only 344 were working—a roughly 32% vacancy. 

What this means is that far fewer checks than needed were being conducted, and fewer samples than required were being tested. These are structural/regulatory gaps. 

How This Relates to the Recent Cough Syrup Deaths

  • In Madhya Pradesh, there were deaths of children linked to consumption of a cough syrup called Coldrif, made by Sresan Pharmaceuticals in Kancheepuram, Tamil Nadu. The syrup was found to contain very high levels of diethylene glycol (DEG), a toxic industrial chemical.

  • An inspection of Sresan’s facility found over 350 violations, including major deficiencies in hygiene, quality assurance, equipment condition, and the absence of required checks and procedures.

So, the CAG’s earlier flagging of drug test shortfalls—fewer inspections, fewer samples—lines up with what appears to have failed in this case. That is, the existing regulatory system had known weaknesses, which may have allowed substandard or adulterated drugs (in this case, the toxic syrup) to be manufactured, distributed, or remain undetected for long.

What Were the Gaps / What Could Have Been Done

Because of the shortfalls flagged by the CAG,

  • There was less frequent on-site inspection of manufacturing units, which might have missed the unsafe practices at the Sresan facility (rusted equipment, unhygienic premises, etc.).

  • Less sample testing means fewer opportunities to detect adulteration (e.g. checking raw materials, inactive ingredients, finished product) before it reaches the market. 

The manpower gap meant fewer inspectors, possibly leading to less oversight or delayed inspections.

What does CAG report say?

Here’s a more detailed breakdown of what the CAG (Comptroller & Auditor General of India) report on Tamil Nadu says, especially with regard to drug inspection, sampling, and regulatory oversight:

Scope & Timing of the Audit

Key Findings & Deficiencies Flagged by CAG

1. Shortfall in Drug Inspections / Facility Checks

  • During 2016-17 to 2020-21, the state’s drug inspectors conducted only ~61% of the targeted drug inspections overall. 

  • The shortfall in inspections in different years ranged between about 34% to 40%:
      • 2016-17: Only 66,331 out of 100,800 inspections → ~34% shortfall 
      • 2017-18: 60,495 / 100,800 → ~40% gap
      • 2018-19: 59,682 / 98,280 → ~39% gap
      • 2019-20: 62,275 / 103,500 → ~40% shortfall 
      • 2020-21: 62,358 / 100,800 → ~38% shortfall

These gaps imply that many drug manufacturing/retail or other facilities were not being regularly inspected as required by regulation.

2. Shortfall in Drug Sample Collection for Testing

  • Alongside inspections, sample collection for quality testing was also well below targets. On average across those years, only ~49% of the required samples were actually collected. 
      • 2017-18: 8,908 / 17,280 → ~48% shortfall 
      • 2018-19: 8,988 / 19,656 → ~54% shortfall 
      • 2019-20: 9,011 / 19,320 → ~53% shortfall 
      • 2020-21: 8,604 / 18,816 → ~54% shortfall 

That means over half the intended sampling for drug-testing was routinely missed in many years.

3. Manpower / Staffing Shortage

  • The report highlights a significant vacancy problem: out of 488 sanctioned drug inspector posts in Tamil Nadu, only 344 were filled during the audit period — about a 32% vacancy rate.

  • Such staffing gaps are likely to reduce the capacity for oversight, inspections, sample collection, monitoring, and enforcing compliance.

4. Weaknesses in the Drug Regulatory Ecosystem

Beyond numbers, the CAG report points to structural and systemic weaknesses:

  • The cumulative effect of missed inspections and sampling suggests that the regulatory machinery was not fully capable of enforcing drug quality norms reliably. 

  • The report implies that these deficiencies could have serious public-health implications, particularly in a domain where adulteration or substandard drugs can cause severe harm. 

  • The gaps also suggest that the state’s drug oversight was under-resourced and under-executed, which might allow unsafe practices, non-compliance, or illicit manufacturing to continue unchecked.

Implications & Relevance to the Cough Syrup Deaths

  • Because inspections and sample testing were often skipped or underdone, regulators may have missed early warning signs at manufacturing units (e.g. deviations in processes, non-sterile conditions, adulteration).

  • The staffing shortfall meant fewer hands available to monitor, follow up, enforce corrective actions, or respond quickly to violations.

  • The report’s findings, released before the tragedy, indicate that the weaknesses flagged by CAG existed in the system prior to the cough syrup deaths — i.e. they were known and unaddressed. 


In short: the CAG report says that Tamil Nadu’s drug regulatory system had been underperforming across multiple key metrics for years, with consistent shortfalls in inspections and sample collection, exacerbated by understaffing. These shortcomings likely weakened the state’s ability to detect, prevent, or act against dangerous defects in medicines — increasing the risk of incidents like the contaminated cough syrup tragedy.

"This Content Sponsored by SBO Digital Marketing.

Mobile-Based Part-Time Job Opportunity by SBO!

Earn money online by doing simple content publishing and sharing tasks. Here's how:

  • Job Type: Mobile-based part-time work
  • Work Involves:
    • Content publishing
    • Content sharing on social media
  • Time Required: As little as 1 hour a day
  • Earnings: ₹300 or more daily
  • Requirements:
    • Active Facebook and Instagram account
    • Basic knowledge of using mobile and social media

For more details:

WhatsApp your Name and Qualification to 9994104160

a.Online Part Time Jobs from Home

b.Work from Home Jobs Without Investment

c.Freelance Jobs Online for Students

d.Mobile Based Online Jobs

e.Daily Payment Online Jobs

Keyword & Tag: #OnlinePartTimeJob #WorkFromHome #EarnMoneyOnline #PartTimeJob #jobs #jobalerts #withoutinvestmentjob"

0 Response to "Cough Syrup Deaths: CAG Flagged Tamil Nadu’s Drug Test Shortfall Year Before Fatal Incidents, Says Report"

Post a Comment

Subscribe to: Post Comments (Atom)